Navigation Links
Enzyme complex could be key to new cancer treatments
Date:4/3/2008

Penn State scientists are the first to observe in living cells a key step in the creation of adenine and guanine, two of the four building blocks that comprise DNA. Also called purines, the two building blocks are essential for cell replication. The findings, which will be published in the 4 April 2008 issue of the journal Science, could lead to new cancer treatments that prevent cancer cells from replicating by interfering with their abilities to make purines.

The group used cervical cancer cells--which have an increased demand for purines due to their rapid rates of replication--to demonstrate that a group of six enzymes is involved in the creation of purines. "Our research shows that these enzymes form a cluster prior to purine formation," said Erin Sheets, an assistant professor of chemistry and a collaborator on the project.

Although other researchers had, in the past, studied the enzymes individually in test tubes, no one, until now, had examined the group of enzymes together in living cells. "This is the first time that anyone has used the appropriate technology to look for this kind of complex in a living cell," said the team's leader Stephen Benkovic, Evan Pugh Professor of Chemistry and holder of the Eberly Family Chair in Chemistry.

Postdoctoral associates Songon An and Ravindra Kumar, from the Benkovic group, studied the enzyme clusters using a technique called fluorescence microscopy, in which fluorescent proteins are attached to molecules of interest and viewed under a special microscope. According to Sheets, the technique makes it easier to observe specific molecules in a cell. "It's like giving a bright orange helmet to your favorite football player so you can more easily monitor his actions," she said.

The researchers attached fluorescent proteins to the enzymes of cells grown in the presence and absence of purines. They found that in the absence of purines, enzymes formed clusters at much higher rates, suggesting that they play a role in the creation of new purines. In contrast, cells also can produce purines by recycling old purine material. Owing to this salvage process, cells do not always need enzyme clusters; indeed, cluster formation was not observed in cells that were grown in the presence of purines. In a key experiment, the researchers were able to influence the association and dissociation of the enzyme cluster by changing the cells' exposure to purines.

Not all of the cells that were grown in the absence of purines contained enzyme clusters. "We think that the enzymes form clusters only when a cell needs purines, and that happens when a cell is required to replicate its DNA at a certain stage in its cell cycle," said Sheets. "Since each of our samples contain cells at different stages of the cell cycle, we did not expect all of them to be actively replicating their DNA. Therefore, we weren't surprised to find that some of our cells did not contain enzyme clusters."

Because purines are necessary for DNA replication and, ultimately, for cell replication, the ability to halt purine synthesis could prove to be a valuable method for treating cancer. "Cancer cells have very high demands for purines," said Benkovic. "If we can find a way to disrupt the formation of this particular enzyme cluster, it could become a potential new target for cancer therapy."


'/>"/>

Contact: Barbara K. Kennedy
science@psu.edu
814-863-4682
Penn State
Source:Eurekalert  

Related medicine news :

1. Elevated liver enzymes associated with higher future mortality
2. Enzyme structure reveals new drug targets for cancer and other diseases
3. Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
4. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
5. First look at an enzyme target for antibacterial and cancer drugs
6. Caught in the act: The dynamic dance of enzymes
7. McGill researchers link enzyme to breast cancer malignancy
8. Telomerase enzyme structure provides significant new target for anti-cancer therapies
9. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
10. Role of a key enzyme in reducing heart disease identified
11. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Enzyme complex could be key to new cancer treatments
(Date:1/24/2017)... ... January 24, 2017 , ... The health insurance industry is ... (AEP) and the Open Enrollment Period (OEP). 2016 was no exception. If anything, ... witnessing higher deductibles, rising premiums, and few choices with their insurance, which is ...
(Date:1/24/2017)... ... , ... The Cruise Web Inc. was recognized today as Northeast ... Annual MSC True Partnerships’ Awards. , The 2016 MSC True Partnerships Awards are ... on overall business growth in revenue and guests and continuous partnership support and innovative ...
(Date:1/24/2017)... ... January 24, 2017 , ... OMI Industries, a worldwide leader ... distribution partnership with Byers Scientific & Manufacturing , a leading designer, engineer ... agreement, OMI Industries formulated a special version of Ecosorb® for Byers Scientific & ...
(Date:1/24/2017)... Hill, N.C. (PRWEB) , ... January 24, 2017 ... ... Trump Administration is the focus of a new report from the Frank ... Kenan-Flagler Business School. , Influential business leaders, academics and policy makers identified concrete ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January 23, 2017 ... the nation’s foremost water advocate and host of the nationally syndicated The Sharon ... America, once again welcomed one of her favorite guests and colleagues, Dr. Gerald ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Md. , Jan. 24, 2017   Intrexon Corporation ... engineering and industrialization of biology to improve the quality of ... has entered into a definitive agreement to acquire GenVec, ... and pioneer in the development of AdenoVerse™ gene delivery technology.  ... GenVec,s expertise in adenoviral vectors and cGMP drug product manufacturing ...
(Date:1/24/2017)... , Jan. 24, 2017   QR ... biopharmaceutical company developing novel therapies for the treatment ... announced the appointment of four world-class key opinion ... new appointments join QR Pharma,s previous roster of ... and direction to support the development of the ...
(Date:1/24/2017)... Research and Markets has announced the addition of the "Optogenetics ... report to their offering. ... Global Optogenetics Market is poised to grow at ... approximately $76.24 million by 2025. Some of the prominent ... using optogentic techniques for neurosciences, quick growth ultrafast laser tools technology, ...
Breaking Medicine Technology: